[Novel Innovation: Can Artificial Intelligence make Rehabilitation more Efficient?]

Demand for Vocational Rehabilitation in Iceland has been steadily rising in recent years where the presence of young patients has increased proportionally the most. It is essential that public spending is efficient without compromising the treatment quality. It is worth exploring if a solution for increasing the efficiency in this healthcare section is to use Artificial Intelligence (AI). An innovative project on developing, testing, and implementing specialised AI software in its services is being performed in Janus Rehabilitation. The software, named Völvan in Icelandic, can identify latent areas of possible interest in patient's circumstances which might affect the outcome of their treatment, and assist specialists in providing timely and appropriate interventions. The accuracy, precision, and recall of its predictions have been verified in two recent publications. Völvan seems to be a promising tool for individualised rehabilitation, where patients are dealing with difficult and complex problems. Janus Rehabilitation is in the process of launching Völvan as an unbiased member of the interdisciplinary teams of specialists. The aim of this report is to introduce Völvan and the associated research.

Determinants of outcome of vocational rehabilitation.

BACKGROUND: Information regarding the determinants of successful vocational rehabilitation (VR) is scarce. OBJECTIVE: Investigate whether sex, duration, quality of life and financial circumstances influence the success of VR. METHODS: The study group consisted of 519 participants (293 women, 56%), who finished VR in the period 2000-2014. The group was divided into the following subgroups: dropouts, unsuccessful and successful VR. Data were collected by questionnaire. RESULTS: Income had the most impact on whether the outcome was successful. Having supplemental income when entering the VR program increased the likelihood of a successful conclusion, odds ratio (OR) 5.60 (95% CI; 2.43-13.59) (p < 0.001), being on sick leave OR 5.02 (95% CI 1.93-13.79) (p < 0.001) or rehabilitation pension OR 1.93 (95% CI 1.07-3.52) (p < 0.03). The participants in the successful sub-group were older (p < 0.06) and stayed in rehabilitation longer (p < 0.001), compared to those who were unsuccessful. However, the effect on OR was limited: 1.03 (95% CI 1.01-1.06) and 1.04 (95% CI 1.02-1.07), respectively. CONCLUSIONS: For this sample, supplemental income appears to be the most important factor for a successful rehabilitation outcome. Checking financial status at the beginning of the rehabilitation process could minimize financial strain and increase the likelihood of success.

The effects of repetitive transcranial magnetic stimulation on depressive symptoms and the P(300) event-related potential.

Changes in the Hamilton Depression Rating Scale and the P(300) auditory event-related potential were assessed in 10 patients with depression before and after a treatment course of five daily sessions of 10 Hz repetitive transcranial magnetic stimulation (rTMS) over the left prefrontal cortex. The patients were initially randomly allocated either to an active or a placebo rTMS treatment. All patients received both types of treatment separated by an interval of 4 weeks. The median Hamilton score decreased by 7 points following active rTMS and by 1 point after sham (p=0.075). Active rTMS was associated with a significant increase in the P(300) amplitude compared with sham (p=0.02). There was no correlation between changes in P(300) measurements and the Hamilton scores after active treatment. We conclude that five daily sessions of left prefrontal rTMS treatment is not of sufficient duration to make a significant improvement in depressive symptoms.

Neuregulin 1 and susceptibility to schizophrenia.

The cause of schizophrenia is unknown, but it has a significant genetic component. Pharmacologic studies, studies of gene expression in man, and studies of mouse mutants suggest involvement of glutamate and dopamine neurotransmitter systems. However, so far, strong association has not been found between schizophrenia and variants of the genes encoding components of these systems. Here, we report the results of a genomewide scan of schizophrenia families in Iceland; these results support previous work, done in five populations, showing that schizophrenia maps to chromosome 8p. Extensive fine-mapping of the 8p locus and haplotype-association analysis, supplemented by a transmission/disequilibrium test, identifies neuregulin 1 (NRG1) as a candidate gene for schizophrenia. NRG1 is expressed at central nervous system synapses and has a clear role in the expression and activation of neurotransmitter receptors, including glutamate receptors. Mutant mice heterozygous for either NRG1 or its receptor, ErbB4, show a behavioral phenotype that overlaps with mouse models for schizophrenia. Furthermore, NRG1 hypomorphs have fewer functional NMDA receptors than wild-type mice. We also demonstrate that the behavioral phenotypes of the NRG1 hypomorphs are partially reversible with clozapine, an atypical antipsychotic drug used to treat schizophrenia.